ACP3 and posterior cortical atrophy: To evaluate the clinical utility of the candidate glycopeptides and facilitate the translation of the MS-based candidate biomarkers to routine clinical implementation in future, we developed easily extendable PRM quantitative assays for ACPP and CLU since promising results were found for aggressive PCa detection based on quantitative DIA analysis23.